Exhibit 99.2

2014 Unaudited Condensed

Interim

Financial

Report

Contents

I Business review of the first nine months of 2014	3
II Unaudited condensed interim financial statements	4
Unaudited consolidated income statement	4
Unaudited consolidated statement of comprehensive income	5
Unaudited consolidated balance sheet	6
Unaudited consolidated statement of changes in equity	7
Unaudited consolidated cash flow statement	8
Selected notes	9
General information	9
Summary of significant accounting policies	9
Segment reporting	13
Other notes	14
1. Significant events and transactions for the period	14
2. Income tax	14
3. Contingencies	14
4. Main risks and uncertainties	14
5. Business combinations	15
6. Financial instruments	17
7. Related parties	17
8. Significant events after balance sheet date	17
9. Exceptional items	17

[Page intentionally left blank]

2

I. Business Review of the First Nine months of 2014

Highlights

• Since Omega Pharma Invest NV is a holding company that holds all shares of its participation, Omega Pharma NV, the business of the company is mainly determined by the business of the Omega Pharma group. Therefore, this business review mainly refers to the Omega Pharma group.

• Turnover grew by 7% compared to the same period of last year, benefitting from the good results of the Top 20 brands (increase of 10%). Double digit sales growth in France, Belgium, Germany, UK, Spain and Portugal. As a consequence of the strong euro, the currency conversion impact mounted to €-5.2 million versus last year.

• Gross margin grew by 9% from 54% on net sales to 56% as the result of an improved product mix.

• Results show that the restructuring of the last years turned around the business and start to pay off.

Key financial figures

Key financial figures for the First Nine months of 2014

(in € million)	YTD Sept 2014		YTD Sept 2013		Year on year evolution
Consolidated turnover		960.7		897.6		+7	%
Gross margin		533.3		487.4		+9	%
Operating profit from continuing operations		180.8		105.5		+71	%

3

II. Unaudited condensed interim financial statements

Unaudited consolidated income statement

(in € thousand)	January- September 2014 Unaudited		% of Net sales			January- September 2013 Unaudited		% of Net sales			Year on year evolution
Net Sales		960 706		100	%		897 599		100	%		+7	%
Cost of goods sold		-427 431		44	%		-410 236		46	%		+4	%
Gross Margin		533 275		56	%		487 363		54	%		+9	%
Distribution expenses		-48 874		5	%		-51 672		6	%		-5	%
Sales and Marketing expenses		-268 496		29	%		-260 193		28	%		+3	%
General Administrative expenses		-42 532		4	%		-42 560		5	%		-0	%
Other operating income/expense, net		-3 756		0	%		3 212		0	%		-217	%
Exceptional items		11 052		1	%		-30 679		3	%		+136	%
Operating Profit		180 669		19	%		105 471		13	%		+65	%
Finance income		3 047		0	%		3 308		0	%		-8	%
Finance cost		-48 630		5	%		-49 732		5	%		-2	%
Net Finance cost		-45 583		5	%		-46 424		5	%		-2	%
Result before income tax		135 086		14	%		59 047		7	%		+129	%
Income tax expense		-14 887		2	%		-16 305		2	%		-9	%
Result after income tax		120 199		13	%		42 742		5	%		+181	%
Of which attributable to the shareholders of the parent company		120 468					42 759
Of which attributable to non-controlling interests		-269					-17

4

Unaudited consolidated statement of total comprehensive income

(in € thousand)	Fair value and other reserves		Cumulative translation adjustments		Retained earnings		Attributable to the shareholders of the parent company		Attributable to non- controlling Interests		Total equity
Profit for the period						42 759		42 759		-17		42 742
Fair value gains on cash flow hedges		2 777						2 777				2 777
Fair value gains on cash flow hedges - Tax effect		-944						-944				-944
Currency translation adjustments (*)				763				763				763
Total comprehensive income for the period ended 30 September 2013		1 833		763		42 759		45 355		-17		45 338

(in € thousand)	Fair value and other reserves		Cumulative translation adjustments		Retained earnings		Attributable to the shareholders of the parent company		Attributable to non- controlling Interests		Total equity
Profit for the period						120 468		120 468		-269		120 199
Fair value losses on cash flow hedges		-3 831						-3 831				-3 831
Fair value losses on cash flow hedges - Tax effect		1 302						1 302				1 302
Currency translation adjustments(*)				471				471				471
Total comprehensive income for the period ended 30 September 2014		-2 529		471		120 468		118 410		-269		118 141

The fair value gains / (losses) and the currency translation adjustments may subsequently be reclassified to the income statement and total € -2.5 million as at 30 September 2014 and € 1.8 million as at 30 September 2013.

(*) There is no tax impact on the cumulative translation adjustments.

5

Unaudited consolidated balance sheet

(in € thousand)	30 September 2014 unaudited		31 December 2013 audited
Non-current assets		1 777 368		1 689 977
Intangible assets		1 629 465		1 555 423
Of which Consolidation goodwill		603 914		580 594
Property, plant and equipment		85 498		79 665
Financial assets		0		1 940
Deferred income tax assets		59 510		41 315
Other non-current assets		2 895		11 634
Current assets		502 763		523 929
Inventories		208 684		191 613
Trade receivables		220 820		210 223
Other current assets		51 674		44 719
Of which Income tax assets		5 022		3 483
Cash and cash equivalents		21 585		77 374
TOTAL ASSETS		2 280 131		2 213 906
EQUITY		700 879		626 799
Share capital and share premium		424 489		424 489
Retained earnings		319 999		243 530
Treasury shares		-34 926		-34 926
Fair value and other reserves		-9 279		-6 750
Cumulative translation adjustments		989		518
Equity attributable to the shareholders of the parent company		701 272		626 861
Equity attributable to non-controlling interests		-393		-62
LIABILITIES		1 579 252		1 587 107
Non-current liabilities		1 247 334		1 145 592
Provisions		1 790		1 754
Pension obligations		13 847		14 013
Deferred income tax liabilities		124 213		106 246
Retail Bond		600 000		600 000
Borrowings (non-current financial liabilities)		491 815		410 586
Other non-current liabilities		1 133		1 072
Derivative financial instruments		14 536		11 921
Current liabilities		331 918		441 515
Borrowings (current financial liabilities)		34 090		41 045
Trade payables		193 992		309 716
Taxes, remuneration and social security		55 554		48 558
Other current payables		48 282		38 619
Derivative financial instruments		0		3 577
TOTAL EQUITY AND LIABILITIES		2 280 131		2 213 906

6

Unaudited consolidated statement of changes in equity

(in € thousand)	Number of shares		Share capital and share premium		Treasury shares		Fair value & other reserves		Cumulative translation adjustments		Retained earnings		Attributable to Shareholders of parent company		Attributable to non- controlling interests		Total equity
Balance at 31 December 2012		685 348 257		424 489		-34 926		-8 541		423		229 812		611 257		-129		611 128
Total comprehensive income for the period ended 30 September 2013								1 833		763		42 759		45 355		-17		45 338
Capital increases
Share split
Dividend												-40 024		-40 024				-40 024
Attributable to non-controlling interests																94		94
Balance at 30 September 2013		685 348 257		424 489		-34 926		-6 708		1 186		232 547		616 588		-52		616 536
Balance at 31 December 2013		685 348 257		424 489		-34 926		-6 750		518		243 530		626 861		-62		626 799
Total comprehensive income for the period ended 30 September 2014								-2 529		471		120 468		118 410		-269		118 141
Capital increases
Share split
Change in percentage of non-controlling interests
Dividend												-43 999		-43 999				-43 999
Attributable to non-controlling interests																-62		-24
Balance at 30 September 2014		685 348 257		424 489		-34 926		-9 279		989		319 999		701 272		-393		700 879

7

Unaudited consolidated cash flow statement

(in € thousand)	January- September 2014 Unaudited		January- September 2013 Unaudited
Profit before income tax		135 086		59 046
Taxes paid		-17 370		-14 591
Adjustments for operational non-cash items		26 419		33 797
Adjustments for interests and financial non-cash items		37 310		37 528
Gross cash flow from operating activities		181 445		115 780
Changes in working capital		-150 480		-203 909
Total cash generated from operating activities		30 965		-88 129
Capital expenditure		-72 578		-65 034
Disposals of investment goods		3 224		1 794
Proceeds from divestments in existing and former holdings		30 753		0
Investments in existing shareholdings (post payments) and in new holdings		-40 269		-5 153
Total cash used in investing activities		-78 870		-68 393
Dividend distribution		-44 003		-40 033
Proceeds from borrowing		67 896		149 931
Interest received		3 423		2957
Interests paid		-34 972		-26 307
Total cash used in financing activities		-7 656		86 548
Net increase/decrease of cash flows for the period		-55 561		-69 974
Cash and cash equivalents - start of the period		77 373		136 881
Gains or losses on currency exchange on liquid assets		-227		-2 609
Cash and cash equivalents - end of the period		21 585		64 298
Total net cash flow of the period		-55 561		-69 974

8

Selected notes

General information

Omega Pharma Invest NV (the ‘Company’) and its subsidiaries (together the ‘Group’) are vendors of high-added-value products and services to pharmacies and other medical sectors. The Group has activities in close to 40 countries.

The Company is a limited liability company, making a public appeal on savings. The Company is incorporated and domiciled in Belgium, having its registered office at Venecoweg 26, 9810 Nazareth, with company number BE 0439 608 834.

The condensed consolidated interim financial statements for the nine months’ period ended 30 September 2014 have been prepared in accordance with IAS 34 ‘Interim Financial Reporting’ as issued by the International Accounting Standards Board (IASB). This document should be read together with the consolidated annual accounts for the period 2013 (including the significant accounting policies) as prepared for the purpose of publication in the United States of America (US) and based on International Financial Reporting Standards as issued by the IASB (further the 2013 Consolidated Financial Statements).

Since the Group prepares condensed consolidated interim financial statements as per and for the nine-month periods ended 30 September 2014 and 2013 for the first time and since the Group otherwise does not prepare quarterly interim financial statements, the third quarter information is not included in these condensed consolidated interim financial statements.

These condensed consolidated interim financial statements have been approved for publication by the Board of Directors of 17 November 2014.

Summary of significant accounting policies

The principal accounting policies applied in preparation of these consolidated interim financial report are identical to those applied in preparation of the consolidated financial statements for the year ended on 31 December 2013.

The preparation of interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates.

In preparing these condensed interim financial statements, the significant judgements made by management in applying the group’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the 2013 Consolidated Financial Statements), with the exception of changes in estimates that are required in determining the provision for income taxes and recognition of deferred tax assets as further detailed further in the notes.

9

A summary of the principal accounting policies can be found in Note 2 to the consolidated financial statements as included in the 2013 Consolidated Financial Statements.

The following new standards, amendments to standards and interpretations are mandatory for the first time for the financial year beginning 1 January 2014. None of the below standards or interpretations had a significant impact on the Group:

• Amendments to IAS 32 ‘Offsetting financial assets and financial liabilities’, effective for annual periods beginning on or after 1 January 2014. The amendments clarify some of the requirements for offsetting financial assets and financial liabilities on the statement of financial position.

• Amendments to IAS 36 ‘Impairment of assets’, effective for annual periods beginning on or after 1 January 2014. The IASB made consequential amendments to the disclosure requirements of IAS 36 when it issued IFRS 13. One of the amendments was drafted more widely than intended. This limited scope amendment corrects this and introduces additional disclosures about fair value measurements when there has been impairment or a reversal of impairment.

• Amendments to IAS 39 ‘Financial instruments: Recognition and measurement’, effective for annual periods beginning on or after 1 January 2014. These amendments provide relief from discontinuing hedge accounting when novation of a derivative designated as a hedging instrument meets certain criteria. Similar relief will be included in IFRS 9 ‘Financial instruments’.

• IFRIC 21 ‘Levies’, effective for annual periods beginning on or after 1 January 2014. IFRIC 21 sets out the accounting for a liability to pay a levy if that liability is within the scope of IAS 37. It also addresses the accounting for a liability to pay a levy whose timing and amount is certain.

The following new standards and amendments to standards have been issued, but are not mandatory for the first time for the financial year beginning 1 January 2014. None of the following standards or interpretations is expected to have a significant effect on the consolidated financial statements of the Group:

• IFRS 9 ‘Financial instruments’, effective for annual periods beginning on or after 1 January 2018. The standard addresses the classification, measurement and derecognition of financial assets and financial liabilities.

• Amendment to IAS 19 ‘Defined benefit plans’, effective for annual periods beginning on or after 1 July 2014. The amendment seeks clarification for the accounting of employee contributions set out in the formal terms of a defined benefit plan.

• Amendment to IFRS 9 ‘financial instruments’ on general hedge accounting, effective for annual periods beginning on or after 1 January 2018. The amendment incorporates the new general hedge accounting model which will allow reporters to reflect risk management activities in the financial statements more closely as it provides more opportunities to apply hedge accounting. These amendments also impact IAS 39 and introduce new disclosure requirements for hedge accounting, thereby impacting IFRS 7, irrespective of the fact whether hedge accounting requirements under IFRS 9 or IAS 39 are used.

10

• Amendment to IFRS 11 ‘Joint arrangements’ on acquisition of an interest in a joint operation, effective for annual periods beginning on or after 1 January 2016. This amendment adds new guidance on how to account for the acquisition of an interest in a joint operation that constitutes a business. The amendments specify the appropriate accounting treatment for such acquisitions.

• Amendment to IAS 16 ‘Property, plant and equipment’ and IAS 38 ‘Intangible assets’ on depreciation and amortisation, effective for annual periods beginning on or after 1 January 2016. In this amendment the IASB has clarified that the use of revenue-based methods to calculate the depreciation of an asset is not appropriate because revenue generated by an activity that includes the use of an asset generally reflects factors other than the consumption of the economic benefits embodied in the asset. The IASB has also clarified that revenue is generally presumed to be an inappropriate basis for measuring the consumption of the economic benefits embodied in an intangible asset.

• IFRS 15 ‘Revenue from contracts with customers’. The IASB and FASB have jointly issued a converged standard on the recognition of revenue from contracts with customers. The standard will improve the financial reporting of revenue and improve comparability of the top line in financial statements globally. Companies using IFRS will be required to apply the revenue standard for annual periods beginning on or after 1 January 2017, subject to EU endorsement.

• Annual improvements (2010-2012 cycle)’ with minor amendments to eight standards, effective for annual periods beginning on or after 1 July 2014. The amendments relate to IFRS 2 ‘Definition of vesting condition’, IFRS 3 ‘Accounting for contingent consideration in a business combination’, IFRS 8 ‘Aggregation of operating segments’, ‘IFRS 8 ‘Reconciliation of the total of the reportable segments’ assets to the entity’s assets’, IFRS 13 ‘Short-term receivables and payables’, IAS 7 ‘Interest paid that is capitalised’, IAS 16/IAS 38 ‘Revaluation method—proportionate restatement of accumulated depreciation’ and IAS 24 ‘Key management personnel’.

• ‘Annual improvements (2011-2013 cycle)’ in response to four issues addressed during the 2011-2013 cycle, effective for annual periods beginning on or after 1 July 2014. The amendments include IFRS 1 ‘Meaning of effective IFRSs’, IFRS 3 ‘Scope exceptions for joint ventures’, IFRS 13 ‘Scope of paragraph 52 (portfolio exception)’ and IAS 40 ‘Clarifying the interrelationship of IFRS 3 Business Combinations and IAS 40 Investment Property when classifying property as investment property or owner-occupied property’.

• ‘Annual Improvements (2012–2014 cycle)’ with amendments to 4 standards, effective for annual periods beginning on or after 1 January 2016. The amendments include IFRS 5, ‘Non-current assets held for sale and discontinued operations’, IAS 19, ‘Employee benefits’, IFRS 7, ‘Financial instruments: disclosures’ and IAS 34, ‘Interim financial reporting’.

Amendments to IFRS 10, ‘Consolidated financial statements’ and IAS 28, ‘Investments in associates and joint ventures’, effective for annual periods beginning on or after 1 January 2016. These amendments address an inconsistency between the requirements in IFRS 10 and those in IAS 28 in dealing with the sale or contribution of assets between an investor and its associate or joint venture. The main consequence of the amendments is that a full gain or loss is recognised when a transaction involves a business (whether it is housed in a subsidiary or not). A partial gain or loss is recognised when a transaction involves assets that do not constitute a business, even if these assets are housed in a subsidiary.

11

Segment reporting

During the first three quarters of 2014, the segment reporting has not changed compared to the first three quarters ended 30 September 2013 and is consistent with the presentation in the 2013 Consolidated Financial Statements to which we refer for further details on the reporting process of the Group.

The segment results for the period ended 30 September 2013 are as follows:

(in EUR thousand)	Total turnover		Inter-segment turnover		Net turnover		Operating result of the segment
Western Europe		601 015		-192 316		408 699		54 644
Belgium		219 663		-15 813		203 850		23 616
France		156 746		-4 034		152 712		24 018
Emerging Markets		161 750		-29 412		132 338		21 932
Not allocated		—		—		—		-18 739
Total Omega Pharma Invest		1 139 174		-241 575		897 599		105 471
Net Finance cost								-46 424
Result before income tax								59 047

The segment results for the period ended 30 September 2014 are as follows:

(in EUR thousand)	Total turnover		Inter-segment turnover		Net turnover		Operating result of the segment
Western Europe		640 947		-189 516		451 431		99 364
Belgium		248 795		-21 186		227 609		22 942
France		172 982		-3 458		169 524		38 818
Emerging Markets		133 553		-21 411		112 142		15 693
Not allocated		—		—		—		3 852
Total Omega Pharma Invest		1 196 277		-235 571		960 706		180 669
Net Finance cost								-45 583
Result before income tax								135 086

The decrease in Net Turnover in the Emerging Markets by some 15% is predominantly due to the impact of political issues in Ukraine and neighbouring regions and the impact thereof on consumer confidence. These circumstances did not have a significant impact on the Group’s financial assets and liabilities.

12

Other notes

1. Significant events and transactions of for the nine-month period ended 30 September 2014

• Increase of borrowings is mainly driven by the investments in capital expenditures and business combinations.

• Decrease of trade payables mainly relates to a timing differences of payments issued and is considered to be temporary.

• Proceeds from divestments predominantly relate to the earn-out received in respect a financial interest that was sold in 2009. The gain realised is included in Exceptional Items in the income statement.

• Dividends for an amount of EUR 44 million were paid during the first nine months of 2014.

2. Income tax

The amount of the income taxes is a management estimate and is based on an expected average effective tax rate of 20% for the entire accounting period 2014, adjusted for one-off events as mentioned below.

The effective tax rate related to the underlying operational profits is lower than last year. The previously unrecognised deferred tax asset in respect of tax losses carried forward at the level of Omega Pharma Invest NV, has been recognised for an amount of EUR 12.1 million. The recoverability is substantiated by a detailed plan. The effective tax rate is further positively impacted by the exceptional income on divestments which are not taxed.

3. Contingencies

During the first nine months of 2014 no material changes occurred to the situation as described in Note 7.1 of the 2013 Consolidated Financial Statements.

4. Main risks and uncertainties

The Group’s activities expose it to a variety of financial risks: market risk (including currency risk, fair value interest rate risk, cash flow interest rate risk and price risk), credit risk and liquidity risk. The interim financial report does not include all financial risk management information and disclosures required in the 2013 Consolidated Financial Statements, and should be read in conjunction with the 2013 Consolidated Financial Statements.

During the first three quarters of 2014 there have been no significant changes in the risk profile of the Group nor is the risk profile of the group expected to change in the fourth quarter of 2014.

13

5. Business combinations

During the first nine months of 2014, Omega Pharma acquired a number of companies:

• Ymea BV, a Dutch company and owner of the Ymea brand. The Group has obtained full control, the entity is consolidated since 1 April 2014.

• A company named OceBio NV, focused on health retail in pharmacies in Belgium and the Netherlands (includes in other in the table below). The Group has obtained full control, the entity is consolidated since 1 January 2014.

• The Group obtained control over Despharma through the acquisition of 100% of the shares. The entity is consolidated since 1 July 2014.

• A few small transactions with minor impact on the balance sheet (below materiality level).

All transactions are accounted for as business combinations.

In conformity with IFRS 3, the purchase price allocation and the goodwill calculation were done on a preliminary basis and may still be modified within twelve months following the acquisition date.

14

	Ymea						Despharma						Others
(in € thousand)	Book value		Fair value adjustments		Book value		Book value		Fair value adjustments		Book value		Book value		Fair value adjustments		Fair value		Book value		Fair value adjustments		Fair value
Non-current assets		1		30.686		30.687		142		0		142		1.528		116		1.644		1.671		30.802		32.473
Intangible assets		0		30.686		30.686		140				140		889		-35		854		1.029		30.651		31.680
Property, plant and equipment		1		0		1		2				2		245		0		245		248		0		248
Other non-current assets		0		0		0								394		0		394		394		0		394
Deferred tax assets		0		0		0								0		151		151		0		151		151
Current assets		3.953		0		3.953		2.002				2.002		3.873		0		3.873		9.828		0		9.828
Cash and cash equivalents		1.608		0		1.608		110				110		235		0		235		1.953		0		1.953
Other current assets		2.345		0		2.345		1.892				1.892		3.638		0		3.638		7.875		0		7.875
Non-current liabilities		0		0		0		0				0		206		0		206		206		0		206
Deferred tax liabilities		0		7.672		7.672						0		0		0		0		0		7.672		7.672
Other non-current liabilities		0		0		0		0				0		206		0		206		206		0		206
Current liabilities		3.239		0		3.239		129				129		3.271		433		3.704		6.639		433		7.072
Net assets acquired		715		23.014		23.729		2.015				2.015		1.924		-317		1.607		4.654		22.697		27.351
Goodwill						7.672						5.745						8.671						21.088
Total consideration						31.401						7.760						10.278						49.439

15

6. Financial instruments

For all financial assets and liabilities the carrying amount is a reasonable approximation of their fair value except for the derivatives that are accounted for at fair value.

The fair value measurement of the derivatives can be categorised as level 2.

The fair value of the interest swaps is calculated as the present value of estimated future cash flows. The fair value of the currency swaps is determined using forward exchange market rates at the balance sheet dates. All inputs that have a significant effect on the fair value are observable, directly or indirectly.

As at 30 September 2014, the Group has unused credit lines available for a total amount of €259 million .

7. Related parties

Related parties refer to the non-executive members of the Board of Directors. The remuneration of the non-executive members of the Board of Directors is determined on an annual basis, for which reason no further details are included in this interim financial report.

8. Significant events after balance sheet date

• In October 2014, Omega Pharma acquired all European rights of XLS from InQpharm.

• On November 6^th, Omega Pharma announced to have entered into a definitive agreement with Perrigo Company plc in which Perrigo has agreed to acquire Omega Pharma for 3.6 billion EUR. The proposed transaction, which has been unanimously approved by the respective Boards of Directors of Perrigo and Omega, is subject to the satisfaction of closing conditions, including customary regulatory approvals. The transaction is expected to close in the first quarter of calendar year 2015.

9. Exceptional items

Exceptional items are defined as those items that are considered by management to be non-recurring or unusual because of their nature. The exceptional items relate to:

• Acquisition costs;

• Restructuring costs;

• Factory or site closure costs;

• Business restructuring costs

• Cost associated with the termination of distribution agreement.

For the nine-months ended 30 September 2014, the exceptional items include EUR 24 million of income and EUR 13 million expenses. The income mainly relates to an earn-out received in respect a financial interest that was sold in 2009. The expenses mainly relate to business restructuring. For the nine-months ended 30 September 2013, the main components of the exceptional items relate to business restructuring and a bad debt provision for a major distributor in Italy.

16